title: Novel small interfering RNA-containing solution protecting donor organs in heart transplantation.
abstract: BACKGROUND
  Ischemia/reperfusion injury is a major factor in graft quality and subsequent function in the transplantation setting. We hypothesize that the process of RNA interference may be used to "engineer" a graft to suppress expression of genes associated with inflammation, apoptosis, and complement, which are believed to cause ischemia/reperfusion injury. Such manipulation of pathological gene expression may be performed by treatment of the graft ex vivo with small interfering RNA (siRNA) as part of the preservation procedure.
  
  
  RESULTS
  Heart grafts from BALB/c mice were preserved in UW solution (control) or UW solution containing siRNAs targeting tumor necrosis factor-alpha, C3, and Fas genes (siRNA solution) at 4 degrees C for 48 hours and subsequently transplanted into syngeneic recipients. Tumor necrosis factor-alpha, C3, and Fas genes were elevated by ischemia/reperfusion injury after 48 hours of preservation in UW solution. Preservation in siRNA solution knocked down gene expression at the level of messenger RNA and protein in the grafts after transplantation. All grafts preserved in siRNA solution showed strong contraction, whereas grafts preserved in control solution demonstrated no detectable contraction by high-frequency ultrasound scanning. siRNA solution-treated organs exhibited improved histology and diminished neutrophil and lymphocyte infiltration compared with control solution-treated organs. Furthermore, the treated heart grafts retained strong beating up to the end of the observation period (>100 days), whereas all control grafts lost function within 8 days.
  
  
  CONCLUSIONS
  Incorporation of siRNA into organ storage solution is a feasible and effective method of attenuating ischemia/reperfusion injury, protecting cardiac function, and prolonging graft survival.
authors.affiliation: Department of Surgery, University of Western Ontario, London, Ontario, Canada.
authors.forename: Xiufen
authors.initials: X
authors.lastname: Zheng
authors.forename: Dameng
authors.initials: D
authors.lastname: Lian
authors.forename: Arthur
authors.initials: A
authors.lastname: Wong
authors.forename: Michael
authors.initials: M
authors.lastname: Bygrave
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Ichim
authors.forename: Mahdieh
authors.initials: M
authors.lastname: Khoshniat
authors.forename: Xusheng
authors.initials: X
authors.lastname: Zhang
authors.forename: Hongtao
authors.initials: H
authors.lastname: Sun
authors.forename: Tobias
authors.initials: T
authors.lastname: De Zordo
authors.forename: James C
authors.initials: JC
authors.lastname: Lacefield
authors.forename: Bertha
authors.initials: B
authors.lastname: Garcia
authors.forename: Anthony M
authors.initials: AM
authors.lastname: Jevnikar
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Min
mesh_terms: D000818:Animals; D003176:Complement C3 / Q000037:antagonists & inhibitors* / Q000235:genetics; D020868:Gene Silencing; D006085:Graft Survival; D016027:Heart Transplantation; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D034741:RNA, Small Interfering / Q000235:genetics*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000235:genetics; D019014:fas Receptor / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: D003176:Complement C3; D034741:RNA, Small Interfering; D014409:Tumor Necrosis Factor-alpha; D019014:fas Receptor